Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-
CK2 inhibitor
LC-MS
anticancer
indeno[1,2-b]indole
pharmacokinetics
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
05 Jun 2021
05 Jun 2021
Historique:
received:
29
04
2021
revised:
28
05
2021
accepted:
02
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-
Identifiants
pubmed: 34198928
pii: ph14060542
doi: 10.3390/ph14060542
pmc: PMC8226678
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell Oncol (Dordr). 2020 Dec;43(6):1003-1016
pubmed: 33052585
Mucosal Immunol. 2020 Sep;13(5):788-798
pubmed: 31988467
Microsc Res Tech. 2002 Mar 15;56(6):465-78
pubmed: 11921349
PLoS One. 2017 Nov 15;12(11):e0188100
pubmed: 29141026
Biochim Biophys Acta. 2015 Jul;1853(7):1693-701
pubmed: 25887626
J Med Chem. 2011 Jan 27;54(2):635-54
pubmed: 21174434
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Mol Cell Biochem. 2011 Oct;356(1-2):209-16
pubmed: 21761203
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
J Med Chem. 2015 Jan 8;58(1):265-77
pubmed: 25272055
Bioorg Med Chem. 2012 Apr 1;20(7):2282-9
pubmed: 22377675
Biochem Biophys Res Commun. 2012 Jul 20;424(1):71-5
pubmed: 22728884
Electrophoresis. 2010 Jan;31(4):634-40
pubmed: 20162588
Biochim Biophys Acta. 2009 May;1793(5):847-59
pubmed: 19339213
Biomed Rep. 2017 Feb;6(2):127-133
pubmed: 28357063
Pharmaceuticals (Basel). 2017 Jan 28;10(1):
pubmed: 28134850
BMC Cancer. 2019 Mar 6;19(1):202
pubmed: 30841886
Mol Cancer Res. 2004 Dec;2(12):712-21
pubmed: 15634760
ChemMedChem. 2017 Oct 20;12(20):1723-1736
pubmed: 28837260
Mol Cell Biochem. 2005 Jun;274(1-2):77-84
pubmed: 16342410
J Transl Med. 2011 Jun 25;9:97
pubmed: 21702981
Transl Oncol. 2019 Jan;12(1):143-153
pubmed: 30316146
Mol Cell Biochem. 2011 Mar;349(1-2):125-37
pubmed: 21125314
Cancer Res. 2009 Oct 15;69(20):8200-7
pubmed: 19826041
Sci Rep. 2012;2:241
pubmed: 22355754
J Biol Chem. 1954 Dec;211(2):969-80
pubmed: 13221602
Biochem Pharmacol. 2004 Nov 15;68(10):1911-22
pubmed: 15476662
Curr Cancer Drug Targets. 2004 Feb;4(1):77-84
pubmed: 14965269
Molecules. 2019 Dec 26;25(1):
pubmed: 31888043
J Pharm Biomed Anal. 2019 Aug 5;172:214-222
pubmed: 31060034
Nat Protoc. 2009;4(3):309-24
pubmed: 19214182
Clin Cancer Res. 2013 Dec 1;19(23):6484-94
pubmed: 24036851
Pharmacol Rev. 1965 Jun;17:101-41
pubmed: 14294030
Bioorg Med Chem Lett. 2013 Oct 15;23(20):5609-13
pubmed: 24012124
PLoS One. 2012;7(7):e40853
pubmed: 22815843
Expert Opin Drug Metab Toxicol. 2011 Mar;7(3):353-64
pubmed: 21332386
Mol Cell Biochem. 2011 Oct;356(1-2):177-84
pubmed: 21750987
Eur J Pharm Biopharm. 2016 Mar;100:66-76
pubmed: 26763536
Curr Med Chem. 2008;15(19):1870-86
pubmed: 18691045
Pharmaceutics. 2020 Dec 06;12(12):
pubmed: 33291351
Curr Protein Pept Sci. 2019;20(6):547-562
pubmed: 30659536
ACS Omega. 2019 Mar 19;4(3):5471-5478
pubmed: 31559376
Eur J Med Chem. 2013 Nov;69:465-79
pubmed: 24090918
Biomed Rep. 2020 Dec;13(6):55
pubmed: 33082952
Front Oncol. 2020 Jun 18;10:893
pubmed: 32626654
Trends Cell Biol. 2002 May;12(5):226-30
pubmed: 12062170
Biotechnol Bioeng. 2019 Jan;116(1):206-226
pubmed: 30367820
Pharmaceuticals (Basel). 2017 Mar 05;10(1):
pubmed: 28273877
Cancer Lett. 2012 Sep 1;322(1):113-8
pubmed: 22387988
Biochem J. 2003 Jan 1;369(Pt 1):1-15
pubmed: 12396231
Cell Mol Life Sci. 2009 Jun;66(11-12):1817-29
pubmed: 19387552
Pharmaceuticals (Basel). 2017 Dec 13;10(4):
pubmed: 29236079
J Cell Biochem. 2004 Sep 1;93(1):2-10
pubmed: 15352156
Adv Enzyme Regul. 2008;48:179-87
pubmed: 18492491
Pharmaceuticals (Basel). 2017 Feb 20;10(1):
pubmed: 28230762
Mol Cell Biol. 2003 Feb;23(3):908-15
pubmed: 12529396